Examining Pharmaceutical Patent Practices & Their Impact on Drug Prices
Examining Pharmaceutical Patent Practices & Their Impact on Drug Prices
While pharmaceutical patents and market exclusivity can incentivize innovation in the United States, various patent practices can also impact the affordability of brand drugs and biologics, especially for debilitating conditions such as rheumatoid arthritis, cancer, and diabetes. BPC will host a panel of experts to discuss the tactics used to delay competition through the patent system and the possible policy solutions to address this important issue.
Featuring:
Fireside Chat:
Markus Meier J.D.
Assistant Director for Healthcare, Federal Trade Commission
Dr. Avik S. A. Roy
President, Foundation for Research on Equal Opportunity
Academic Panel:
Robin Feldman J.D.
Arthur J. Goldberg Distinguished Professor of Law, Director of the Center for Innovation at University of California Hastings
Arti Rai J.D.
Elvin R. Latty Professor of Law and Faculty Director, The Center for Innovation Policy at Duke Law School
Melissa Wasserman J.D., PhD
Charles Tilford McCormick Professor of Law, University of Texas at Austin School of Law
Michael Carrier J.D.
Distinguished Professor, Rutgers Law School, Co-Director, Rutgers Institute for Information Policy and Law Rutgers School of Law
Moderator: Dr. Anand Parekh
Chief Medical Advisor, Bipartisan Policy Center
Stakeholder Panel:
Tahir Amin, L.L.B, Dip. LP
Co-Founder and Co-Executive Director, I-MAK
Melissa Brand J.D.
Associate Counsel, Biotechnology Innovation Organization
Karin Hessler J.D.
Assistant General Counsel, Association for Accessible Medicines
Moderator: Charles Duan J.D.
Director of Technology and Innovation, R Street
RSVP here.
